Fighting the epidemic
At the beginning of the new year 2020, the new coronavirus pneumonia (2019-nCoV) swept across China like a storm. In this "epidemic", we were united in overcoming the difficulties and were about to see the dawn.
However, just when we were breathing a sigh of relief, the virus broke out worldwide and we started to worry again.
Novel Coronavirus Pneumonia, is a new type of coronavirus infection resulting in the development of pneumonia in human beings. At present, there is no specific drug for the disease. According to the "Diagnostic and Treatment Plan for New Coronavirus Sense Pneumonia (Sixth Edition)" issued by the National Health Commission, antiviral treatment method, antiviral treatment can be tried with α-interferon (IFNα) nebulised inhalation has been written into the treatment guideline.
Nebulised drug delivery
Nebulised inhalation therapy involves dispersing drugs or water through an inhalation device into a mist or particles suspended in the gas, which are deposited in the respiratory tract and lungs by inhalation, thus achieving the effect of localised treatment in the respiratory tract as well as in the lungs.
Compared with other routes of drug delivery, nebulised inhalation therapy can act directly on the organs, and has the advantages of fast effect, low dosage and high local drug concentration. The lungs, as the deposition site of active pharmaceutical ingredients, often achieve good therapeutic effects rapidly with lower drug dosages. From the combination of theory and practice, we can find that nebulised inhalation therapy, in the future, may become a trend in lung treatment.
Drug particle requirements
For nebulised inhalation therapy, the size of drug particles has strict requirements, and it is usually believed that drug particles with a particle size of 0.5-7 μm can reach the lungs to play a role in the drug effect, and most of them should be below 5 μm to ensure that the drug can be efficiently deposited into the lungs to take effect. Effective nebulised particle diameter refers to the size of the nebulised particles that are deposited in the airways and lungs with therapeutic value, and its size has a direct impact on the location of drug deposition.
Research has found that the nebulised particles are not the bigger the better, nor the smaller the better, the drug nebulised particles diameter in the 0.5-5μm range of the best therapeutic effect.
Nebulisation technology
Among the nebulisation technologies, ultrasonic microporous nebulisation tablets and ultrasonic nebulisation tablet solutions are the most common. Ultrasonic microporous nebulisation, is driven by a piezoelectric ceramic ring to the metal plate 100,000 times per second high-frequency vibration, the liquid from the middle of the metal plate of microporous extrusion, nebulised into tiny particles, liquid particles particle size of about 0.3-7µm between.
Ultrasonic atomiser piece, is through the transducer plate to produce 1.7-2.4 million times per second high-frequency vibration, the surface of the transducer plate liquid broken into tiny particles, the liquid particles particle size is about 0.3-7µm between.
Audiowell Nebuliser
As a leading provider of nebulisation industry, Audiowell has obtained more than a hundred patents, and the annual sales of nebulisation transducer products are more than 20 million pieces, which are widely used in the fields of mesh nebuliser, medical nebuliser and so on.
And with nearly 20 years of experience and technology accumulation in the field of nebulisation, we have introduced safe, efficient, intelligent and cost-effective nebulisation solutions.
Focus on us